| Market Cap | 252.94B | P/E | 20.23 | EPS this Y | 17.20% | Ern Qtrly Grth | 20.60% |
| Income | 12.57B | Forward P/E | 12.02 | EPS next Y | -14.20% | 50D Avg Chg | 1.00% |
| Sales | 57.35B | PEG | -18.09 | EPS past 5Y | 19.00% | 200D Avg Chg | -2.00% |
| Dividend | 4.00% | Price/Book | 17.26 | EPS next 5Y | -0.57% | 52W High Chg | -19.00% |
| Recommedations | 2.20 | Quick Ratio | 0.62 | Shares Outstanding | 1.77B | 52W Low Chg | 34.00% |
| Insider Own | 0.11% | ROA | 8.14% | Shares Float | 1.77B | Beta | 0.69 |
| Inst Own | 70.86% | ROE | 92.71% | Shares Shorted/Prior | 11.38M/13.85M | Price | 143.06 |
| Gross Margin | 70.73% | Profit Margin | 22.04% | Avg. Volume | 5,420,757 | Target Price | 158.85 |
| Oper. Margin | 33.06% | Earnings Date | Oct 27 | Volume | 4,275,507 | Change | 0.03% |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Argus Research | Buy | Aug 24, 22 |
| UBS | Neutral | Aug 1, 22 |
| Morgan Stanley | Overweight | Aug 1, 22 |
| Barclays | Equal-Weight | Aug 1, 22 |
| Atlantic Equities | Neutral | Aug 1, 22 |
| Morgan Stanley | Overweight | Jul 8, 22 |
| SVB Leerink | Underperform | May 23, 22 |
| Morgan Stanley | Overweight | May 2, 22 |
| Wells Fargo | Overweight | May 2, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SEVERINO MICHAEL | Vice Chairman Vice Chairman | May 23 | Option | 104.59 | 79,801 | 8,346,387 | 231,904 | 05/25/22 |
| SEVERINO MICHAEL | Vice Chairman Vice Chairman | May 23 | Sell | 151.16 | 79,801 | 12,062,719 | 152,103 | 05/25/22 |
| Gosebruch Henry O | EVP, Chief Strategy.. EVP, Chief Strategy Officer | May 16 | Option | 54.86 | 83,960 | 4,606,046 | 125,583 | 05/20/22 |
| Gosebruch Henry O | EVP, Chief Strategy.. EVP, Chief Strategy Officer | May 16 | Sell | 155 | 83,960 | 13,013,800 | 41,623 | 05/20/22 |
| SEVERINO MICHAEL | Vice Chairman Vice Chairman | May 16 | Option | 78.23 | 200,000 | 15,646,000 | 252,103 | 05/18/22 |
| SEVERINO MICHAEL | Vice Chairman Vice Chairman | May 16 | Sell | 154.58 | 200,000 | 30,916,000 | 152,103 | 05/18/22 |
| SEVERINO MICHAEL | Vice Chairman Vice Chairman | May 06 | Option | 57.21 | 300,000 | 17,163,000 | 252,103 | 05/10/22 |
| SEVERINO MICHAEL | Vice Chairman Vice Chairman | May 06 | Sell | 151.2 | 300,000 | 45,360,000 | 152,103 | 05/10/22 |
| Stewart Jeffrey Ryan | EVP, Chief Commercia.. EVP, Chief Commercial Officer | Mar 24 | Option | 58.88 | 27,690 | 1,630,387 | 88,631 | 03/25/22 |
| Stewart Jeffrey Ryan | EVP, Chief Commercia.. EVP, Chief Commercial Officer | Mar 24 | Sell | 159.2 | 27,690 | 4,408,248 | 60,941 | 03/25/22 |
| Durkin Brian L | VP, Controller VP, Controller | Mar 09 | Option | 79.02 | 11,682 | 923,112 | 37,722 | 03/11/22 |
| Durkin Brian L | VP, Controller VP, Controller | Mar 09 | Sell | 150 | 18,628 | 2,794,200 | 19,094 | 03/11/22 |
| Gosebruch Henry O | EVP, Chief Strategy.. EVP, Chief Strategy Officer | Mar 01 | Sell | 148.12 | 25,000 | 3,703,000 | 16,623 | 03/02/22 |
| Gosebruch Henry O | EVP, Chief Strategy.. EVP, Chief Strategy Officer | Feb 25 | Sell | 148.43 | 15,000 | 2,226,450 | 41,623 | 03/01/22 |
| Michael Robert A. | Vice Chairman Vice Chairman | Feb 25 | Sell | 148.32 | 43,105 | 6,393,334 | 37,877 | 03/01/22 |
| Strom Carrie C | SVP & Pres Global Al.. SVP & Pres Global Allerg Aesth | Feb 07 | Sell | 141.17 | 2,396 | 338,243 | 42,499 | 02/08/22 |
| AUSTIN ROXANNE S | Director Director | Nov 02 | Sell | 116.42 | 71,844 | 8,364,078 | 49,284 | 11/04/21 |
| Sorg Elaine K. | SVP, US Commercial O.. SVP, US Commercial Operations | Aug 25 | Sell | 120 | 13,080 | 1,569,600 | 11,595 | 08/25/21 |
| Sorg Elaine K. | SVP, US Commercial O.. SVP, US Commercial Operations | Aug 25 | Option | 114.36 | 7,080 | 809,669 | 18,675 | 08/25/21 |
| Sorg Elaine K. | SVP, US Commercial O.. SVP, US Commercial Operations | Feb 24 | Option | 86.26 | 20,195 | 1,742,021 | 52,946 | 02/24/21 |
| Sorg Elaine K. | SVP, US Commercial O.. SVP, US Commercial Operations | Feb 24 | Sell | 105 | 20,195 | 2,120,475 | 32,751 | 02/24/21 |
| RICHMOND TIMOTHY J. | EVP, Chief HR Office.. EVP, Chief HR Officer | Dec 01 | Option | 51.42 | 51,990 | 2,673,326 | 51,990 | 12/01/20 |
| RICHMOND TIMOTHY J. | EVP, Chief HR Office.. EVP, Chief HR Officer | Dec 01 | Sell | 105 | 51,990 | 5,458,950 | 12/01/20 | |
| SALEKI-GERHARDT AZITA | EVP, Operations EVP, Operations | Nov 12 | Option | 24.21 | 4,800 | 116,208 | 118,667 | 11/12/20 |
| SALEKI-GERHARDT AZITA | EVP, Operations EVP, Operations | Nov 12 | Sell | 93.61 | 4,800 | 449,328 | 113,867 | 11/12/20 |
| GONZALEZ RICHARD A | Chairman of the Boar.. Chairman of the Board and CEO | Nov 12 | Option | 56.87 | 194,154 | 11,041,538 | 512,796 | 11/12/20 |
| GONZALEZ RICHARD A | Chairman of the Boar.. Chairman of the Board and CEO | Nov 12 | Sell | 96.76 | 231,604 | 22,410,003 | 318,642 | 11/12/20 |